AC
EGRX

Aristides Capital’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Aristides Capital’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-16,451
Closed -$86K – 385
2023
Q4 		$86K Buy
+16,451
New +$162K 0.03% 250

Other funds holding EGRX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Aristides Capital's EGRX Position: Q1 2024 in Review

Aristides Capital sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2024, closing a stake of 16,451 shares — an estimated $86K sold.

Aristides Capital first reported a position in EGRX in Q4 2023 and held it in 1 quarter. The position peaked at $86K in Q4 2023. 91 funds tracked by Wall St. Rank hold EGRX as of Q1 2024.

  • Aristides Capital reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
  • Aristides Capital sold 16,451 Eagle Pharmaceuticals, Inc. shares in Q1 2024, an estimated $86K.
  • Aristides Capital first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2023 and held it in 1 quarter.
  • Aristides Capital's Eagle Pharmaceuticals, Inc. position peaked at $86K in Q4 2023.
  • 91 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2024.

Based on Aristides Capital's 13F filing for Q1 2024, filed 15 May 2024.